Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00949650
- Locations
- 🇦🇷
Imcaba S.R.L., Capital Federal, Argentina
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇧🇷Hospital São Lucas da Pontifícia Universidade Católica, Porto Alegre, Brazil
Study of Participants With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 361
- Registration Number
- NCT00948675
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States
TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00940069
- Locations
- 🇨🇳
HuNan province tumor hospital, ChangSha, Hunan, China
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Conditions
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 347
- Registration Number
- NCT00932893
- Locations
- 🇺🇸
UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸The Ohio State University Hospital East, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00923273
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT00921310
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT00916630
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 12
- Registration Number
- NCT00907179
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00906282
- Locations
- 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 6
- Registration Number
- NCT00895648
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.